^
    over1year
    GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer. (PubMed, BMC Womens Health)
    We hypothesized that GEMIN4 may be the potential target for the treatment of BLBC.
    Journal
    |
    acalisib (GS-9820)
    almost2years
    Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression. (PubMed, Cancer Res Commun)
    We demonstrate that pan Bcl-2 family inhibition (ABT-263, rER: 1.52-1.56) or Bcl-xL specific inhibition (WEHI-539, A-1331852; rER: 1.31-2.00) radiosensitized wild-type PIK3CA/PTEN TNBC (MDA-MB-231, CAL-120) but failed to radiosensitize mutant PIK3CA/PTEN TNBC (rER: 0.90 - 1.07; MDA-MB-468, CAL-51, SUM-159). In vivo, ABT-263 or A-1331852 in combination with RT decreased tumor growth and increased tumor tripling time (p < 0.0001) in PIK3CA/PTEN wild-type TNBC cell line and patient-derived xenografts. Collectively, this study provides the preclinical rationale for early phase clinical trials testing the safety, tolerability, and efficacy of Bcl-xL inhibition and RT in women with wild-type PIK3CA/PTEN wild-type TNBC at high risk for recurrence.
    Journal • PARP Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3)
    |
    PIK3CA mutation • MCL1 overexpression • MCL1 expression • PIK3CA wild-type
    |
    navitoclax (ABT 263) • A-1331852 • acalisib (GS-9820)
    over3years
    High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. (PubMed, Cancers (Basel))
    We conducted a two-stage drug-screen to investigate the impact of miR-30 family members (miR-30a-30e) on sensitivity to doxorubicin and lapatinib in six breast cancer cell lines HCC1937, HCC1954, MDA-MB-361, MCF7, MDA-MB-436 and CAL-120, using drug sensitivity scores (DSS) to compare the miR-30 family mimics to their specific inhibitors. According to the pathway analysis, the miR-30 family has a suppressive effect on cell motility and metastasis in breast cancer. Our results suggest prognostic and predictive potential for the miR-30 family, which warrants further investigation.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MIR30D (MicroRNA 30d) • MIR30E (MicroRNA 30e)
    |
    HER-2 positive • ER negative • miR-30d expression
    |
    lapatinib • doxorubicin hydrochloride • acalisib (GS-9820)